Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0000950170-25-111753·Inozyme Pharma, Inc.
Schedule 13D ownership disclosure
INOZYME PHARMA INC
Common Stock, par value $0.0001 per share · CUSIP: 45790W108
Event date: 2025-07-01
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Pivotal bioVenture Partners Fund I, L.P.Reported CIK 0001695076
Shares: 0 · Class: 0%
- Pivotal bioVenture Partners Fund II, L.P.Reported CIK 0001857522
Shares: 0 · Class: 0%
- Pivotal bioVenture Partners Fund II G.P. Ltd
Shares: 0 · Class: 0%
- Pivotal bioVenture Partners Fund I G.P., L.P.Reported CIK 0001752862
Shares: 0 · Class: 0%
- Pivotal bioVenture Partners Fund I U.G.P. LtdReported CIK 0001752847
Shares: 0 · Class: 0%
- Pivotal Partners Ltd
Shares: 0 · Class: 0%
- Pivotal Life Sciences Holdings Limited
Shares: 0 · Class: 0%
- Nan Fung Life Sciences Holdings Limited
Shares: 0 · Class: 0%
- NF Investment Holdings Limited
Shares: 0 · Class: 0%
- Nan Fung Group Holdings LimitedReported CIK 0001782539
Shares: 0 · Class: 0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000950170-25-111753
- Form type
- SCHEDULE 13D/A
- Filer
- Inozyme Pharma, Inc.
- CIK
- CIK 1693011
- Filed
- Aug 27, 2025
- Reporting period
- Jul 01, 2025
- Description
- Schedule 13D beneficial ownership